CME Group (CME) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive but not a slam dunk — ADV is the key swing factor, and with Q2 ADV already reported at 29.8M contracts (second-highest Q2 ever, +~19% YoY in June), the volume bar is cleared; the debate is whether RPC compression and expense growth will offset the volume tailwind enough to drive a meaningful EPS beat.

Heading into Q2 2026 earnings, CME's setup is defined by a powerful volume backdrop offset by persistent RPC headwinds and a notable leadership transition overhang. The company has already disclosed that Q2 2026 ADV reached 29.8 million contracts — the second-highest Q2 on record — with record June ADV of 30.6 million contracts (+19% YoY), providing strong top-line visibility ahead of the print. However, consensus estimates for Q2 ADV (~30.3M) and RPC (~$0.670) imply a modest beat on volume but continued compression on rate, a dynamic management was already defensive about on the Q1 call when Q1 RPC came in at $0.652 vs. the prior-year $0.690.

Estimate trajectory has been mixed: Q2 revenue estimates have been revised slightly downward since the Q1 print (from ~$1.709B to ~$1.678B), reflecting RPC compression concerns even as volume momentum remains strong, while full-year 2026 estimates have held relatively stable. Management's tone on the Q1 call was highly confident — record results across all six asset classes, record market data revenue, and a record adjusted operating margin — but the stock has sold off sharply since earnings (down ~17% from the Q1 print date through today), driven by the June 17 CEO transition announcement (Terry Duffy stepping down, Lynne Fitzpatrick named CEO effective March 2027) and broader market rotation away from exchange names. The stock now trades at a meaningful discount to its post-Q1 level, suggesting the bar for a positive reaction is lower, but the CEO transition introduces a new uncertainty premium. The single biggest wildcard is whether management provides any color on Q3 volume trends and the trajectory of the CME-FICC cross-margining expansion to end-user clients, which could be a significant incremental revenue driver not yet in consensus.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a

Key Takeaway: Consensus is a moderate bar on volume (Q2 ADV already confirmed at 29.8M vs. ~30.3M consensus, a slight miss on the headline but June alone was a record 30.6M) —

RPC is the bigger swing factor: if RPC comes in above the ~$0.670 consensus estimate, that is the most likely path to an EPS beat given the volume is largely known.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha Consensus and Actuals Data. Note: Q2 2026 ADV has been partially disclosed via CME's monthly volume reports (May ADV: 33.2M record; June ADV: 30.6M record; Q2 2026 total ADV: 29.8M, second-highest Q2 ever). Consensus estimates reflect Visible Alpha as of July 21, 2026. YoY change for revenue/EPS/margin reflects consensus vs. Q2 2025 actual.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top 2 KPIs: Total Average Daily Volume (ADV) and Diluted Operating EPS

Pattern: CME consistently misses ADV consensus (7 of last 8 quarters) — the street tends to set the volume bar slightly too high — while EPS beats are more common (6 of last 8 quarters), suggesting cost discipline and RPC management provide a buffer even when volumes disappoint. This pattern implies the EPS bar is more achievable than the ADV bar heading into Q2 2026. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management's guidance posture is unchanged since the Q1 2026 earnings call — the only formal guidance is the FY2026 adjusted expense target of ~$1.695B (excl. license fees) — but the

Key Takeaway: Management's guidance posture is unchanged since the Q1 2026 earnings call — the only formal guidance is the FY2026 adjusted expense target of ~$1.695B (excl. license fees) — but the June 17 CEO transition announcement is a material tone shift that introduces leadership uncertainty not present at the time of the last print.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Q2 2026 estimates have been revised

Key Takeaway: Q2 2026 estimates have been revised

Key Takeaway: Q2 2026 estimates have been revised modestly lower since the Q1 print — revenue down ~1.9% and EPS down ~2.4% — reflecting RPC compression concerns, while FY2026 estimates have been more stable (revenue -0.5%, EPS -0.7%). The gap between current consensus and the post-Q1 baseline represents a cushion rather than a risk: the street has already de-risked the quarter.

Source: Visible Alpha Consensus and Actuals Data. The most notable revision since Q1 earnings is the RPC estimate, which has been cut ~3.6% for Q2 2026 (from $0.695 to $0.670), reflecting the market's growing conviction that volume tiering at elevated ADV levels, micro product mix shift, and member trading dynamics will continue to compress the weighted average rate. ADV estimates have actually been revised slightly higher (+1.3% for Q2), consistent with the strong monthly volume data already disclosed. The net effect is a ~2.5% EPS cut for Q2 — a modest de-risking that sets a lower bar.

5. Stock Performance

Key Takeaway: CME has significantly underperformed both CBOE and ICE since the Q1 2026 earnings date — down ~17% vs. CBOE down ~8% and ICE down ~13% — driven primarily by the June 17 CEO transition announcement and broader de-rating of exchange names, not by estimate revisions. The stock now trades at a meaningful discount to its post-Q1 level, suggesting sentiment rather than fundamentals is the primary driver.

CME vs. CBOE vs. ICE — Indexed Price Performance Since Q1 2026 Earnings (April 22, 2026 = 100). Source: Stock Price Data.

CME opened Q2 at $285.71 on April 22 (Q1 earnings day) and traded as high as $305.12 on May 18 before a sharp reversal. The stock fell precipitously in late May and June, with the most significant single-day drop coinciding with the June 17 CEO transition announcement (Terry Duffy stepping down, Lynne Fitzpatrick named CEO effective March 2027). By June 25, CME had fallen to $225 — a ~21% decline from the May peak. The stock has partially recovered to ~$237 as of July 21, 2026, but remains ~17% below the Q1 earnings date close. CBOE (down ~8%) and ICE (down ~13%) have also sold off but significantly less, suggesting CME-specific factors (CEO transition, RPC compression narrative) are driving the underperformance beyond sector-wide pressure. The multiple de-rating creates a lower bar for a positive earnings reaction.

6. Material News & Developments

Key Takeaway: The CEO transition announcement on June 17 is the single most important development since Q1 earnings — it triggered a sharp sell-off and introduces a leadership uncertainty premium that will likely be a central topic on the Q2 call. The strong Q2 volume data (record May and June ADV) is a meaningful positive offset.

• June 17, 2026 — CEO Transition Announced: Terry Duffy (Chairman & CEO for 10+ years) to become Executive Chairman; Lynne Fitzpatrick (current President & CFO) named CEO effective March 1, 2027. CFO search underway.
• Implication: Triggered a ~8% single-day stock decline; introduces leadership uncertainty and CFO vacancy risk. Fitzpatrick is a 20-year CME veteran with deep financial expertise, limiting execution risk, but the market is pricing in a transition premium. Expect significant Q&A on the call.
• July 2, 2026 — Record Q2 2026 Volume Disclosed: CME reported Q2 2026 ADV of 29.8 million contracts (second-highest Q2 ever), with record June ADV of 30.6 million contracts (+19% YoY). All-time monthly records for equity index and agricultural products in June.
• Implication: Provides strong top-line visibility ahead of earnings; volume bar is largely cleared. The debate shifts to RPC and expense management.
• June 2, 2026 — Record May ADV of 33.2 Million Contracts: CME reported its highest May ADV on record, up 15% YoY.
• Implication: Confirms Q2 volume momentum was broad-based and not just a June spike.
• May 29, 2026 — 24/7 Crypto Trading Goes Live: CME launched 24/7 crypto futures trading as scheduled, with meaningful contract volume traded over the inaugural weekend.
• Implication: Execution on a key strategic initiative; incremental volume upside not yet in consensus. Management likely to provide early traction data on the Q2 call.
• May 29, 2026 — CFTC Approves Kalshi Bitcoin Perpetual Contract: The CFTC approved Kalshi’s Bitcoin perpetual futures contract via a 40.3 full review, a development CME management views with “deep disappointment.”
• Implication: Regulatory risk to CME’s competitive moat; management has not committed to listing perpetuals. Could be a significant Q&A topic. CME argues perpetuals are structurally incompatible with institutional hedging and inconsistent with the Commodity Exchange Act.
• April 30, 2026 — CME-FICC Cross-Margining Expansion to End-User Clients: SEC and CFTC approved expansion of the CME-FICC cross-margining program to end-user clients, effective April 30. Management cited potential savings of “upward of 80%” for client books.
• Implication: Significant competitive differentiator and potential incremental revenue driver; not yet in consensus estimates. Early adoption data on the Q2 call could be a positive catalyst.
• April 27, 2026 — CME Amends $7 Billion Credit Facility: CME amended its $7 billion credit facility to bolster clearing house liquidity.
• Implication: Prudent risk management in a volatile macro environment; no material financial impact but signals proactive balance sheet management.
• June 11, 2026 — Rothschild & Co Upgrades CME to Buy from Neutral: The only analyst rating change since Q1 earnings was a single upgrade.
• Implication: Modest positive signal; no major downgrades despite the stock’s underperformance, suggesting the sell-side views the CEO transition sell-off as an overreaction.
• Ongoing — S&P DJI / HyperLiquid IP Dispute: S&P Dow Jones Indices listed S&P 500 perpetual futures on HyperLiquid without prior notice to CME, confirmed by management as infringing on CME’s IP/license agreement. Legal action underway.
• Implication: Headline risk; management expects resolution but timeline uncertain. Could weigh on sentiment if unresolved.

7. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peer commentary since Q1 earnings is broadly constructive for CME’s Q2 setup — ICE and CBOE both reported record Q1 results with strong open interest carry-forward into Q2, and conference commentary from NDAQ and ICE in May–June confirms a favorable macro backdrop (strong corporate earnings, elevated retail engagement, constructive regulatory environment) for derivatives volumes in Q2. The CFTC’s approval of perpetual futures is the key industry-wide risk flagged by all peers.

Note: Only commentary from peers about Q2 2026 current quarter conditions (i.e., post-Q1 earnings calls and conference appearances in May–June 2026) is included below. Q1 2026 results commentary from peers is included only where it provides explicit forward-looking read-through for Q2.

ICE (Intercontinental Exchange) — Q1 2026 Earnings Call (April 30) & Conference Commentary (May 27, June 3)

• Open Interest Carrying Forward into Q2 (April 30 Earnings Call): ICE reported that total futures and options open interest reached a new record in the week of April 30, up 23% YoY, with energy open interest through April remaining up 6%. ICE management stated: “Total open interest across futures and options hit new records over the past week alone, growing more than 20%… rising open interest alongside record volumes signals that customers are building and maintaining positions, not speculating and exiting.”
• CME Read-Through: Elevated open interest at ICE is a strong leading indicator for CME’s own open interest and volume trajectory in Q2. CME’s own open interest reached ~135 million contracts (all-time high) as of the June 2026 conference, consistent with this read-through.
• Q2 2026 Expense Guidance (April 30 Earnings Call): ICE guided Q2 2026 adjusted operating expenses to remain consistent with Q1, in the range of $1.030–$1.040 billion. This signals disciplined cost management across the exchange sector heading into Q2.
• CME Read-Through: Consistent with CME’s own FY2026 expense guidance of ~$1.695B (excl. license fees); no indication of sector-wide cost inflation that would pressure CME’s expense guidance.
• Macro Environment & Volume Outlook (Bernstein Conference, May 27): ICE described its “all-weather model” as working effectively, with interest rate derivative markets as its “best and fastest-growing product.” Energy revenues have nearly doubled over three years due to geopolitical supply chain rewiring (Russia-Ukraine, Iran/Hormuz). ICE noted: “It’s not just more volume, but we actually have more participants… those participants in order to manage risk are consuming more data. So there’s a flywheel effect.”
• CME Read-Through: Directly positive for CME’s interest rate and energy ADV in Q2. CME’s WTI crude market share has grown to “north of 79–80%” during stress periods per CME management. The “flywheel effect” of more participants consuming more data also supports CME’s market data revenue growth trajectory.
• Perpetual Futures & Regulatory Landscape (Piper Sandler Conference, June 3): ICE acknowledged the CFTC’s approval of Kalshi’s Bitcoin perpetual contract and is actively engaged with regulators (CFTC, FCA, MAS) on the topic. ICE has partnered with OKX to launch perpetuals on crude oil for overseas customers but views perpetuals as primarily a retail/speculative product: “For commercial participants, the economic structure of a perpetual… does not fulfill the need for understanding a forward curve.” ICE is also narrowing the window of non-traditional trading by extending hours on Friday/Monday in response to DeFi competition.
• CME Read-Through: Validates CME’s own position that perpetuals do not serve institutional hedging needs. However, ICE’s more pragmatic approach (partnering with OKX, engaging regulators) contrasts with CME’s more adversarial stance, which could be a Q&A topic on the Q2 call.

CBOE Global Markets — Q1 2026 Earnings Call (May 1)

• Derivatives Volume Momentum & Macro Backdrop (May 1 Earnings Call): CBOE reported record Q1 net revenue of $729M (+29% YoY) and record adjusted diluted EPS of $3.70 (+48% YoY), driven by SPX options ADV up 34% YoY to 4.9M contracts. CBOE described a “supportive macro environment for our derivatives business” and noted that in March, as the macro outlook shifted with the Iran war, non-0DTE options jumped over 26% while 0DTE options grew 6% — demonstrating the breadth of the derivatives toolkit across market environments.
• CME Read-Through: The same macro volatility (Iran conflict, tariff uncertainty, rate expectations) that drove CBOE’s record Q1 also drove CME’s record Q1 ADV. CBOE’s commentary that “the macro environment is supportive” heading into Q2 is a positive read-through for CME’s Q2 volume environment.
• Event Contracts & Competitive Dynamics (May 1 Earnings Call): CBOE stated it intends to expand its event contract strategy beyond index-based outcomes, including CFTC-regulated futures or swaps that are also event contracts. CBOE is “super keen on coming to market with company-specific contracts.”
• CME Read-Through: CBOE is moving into CME’s territory on event/prediction contracts. CME has a head start (150,000+ new accounts, 220M+ contracts traded since December 2025), but CBOE’s entry signals the space is becoming more competitive. Management may be asked about competitive positioning on the Q2 call.

Nasdaq (NDAQ) — Q1 2026 Earnings Call (April 23) & Conference Commentary (June 4, June 9)

• Q2 2026 Macro Themes (Piper Sandler Conference, June 4): Nasdaq’s President Tal Cohen described the Q2 2026 macro picture as “volatile, but recently trending in a more favorable direction” with “capital markets activity picking up.” Key constructive factors: strong corporate earnings, AI as a backdrop, constructive regulatory environment (both SEC and CFTC), and high retail engagement. VIX has been “pretty well behaved” despite intraday volatility.
• CME Read-Through: Directly positive for CME’s Q2 volume environment. A “constructive regulatory backdrop” and “high retail engagement” are tailwinds for CME’s prediction markets/event contracts and micro product volumes. The “favorable direction” macro comment is consistent with CME’s own open interest hitting all-time highs in June.
• Q2 2026 Volume Drivers (Morgan Stanley Conference, June 9): Nasdaq confirmed that through April and May, the key macro themes driving trading activity were: (1) strong corporate earnings, (2) strong retail engagement, (3) constructive regulatory backdrop from SEC and CFTC, and (4) the AI trade as a strong tailwind. Nasdaq’s index options business grew over 60% YoY, and 0DTE options on single stocks (Mag Seven, Broadcom, IBIT) showed strong early traction with liquidity up 15–20%.
• CME Read-Through: The 60%+ growth in Nasdaq’s index options business is a read-through for CME’s equity index ADV in Q2. Strong retail engagement and 0DTE momentum are consistent with CME’s own micro equity index options growth. The AI trade tailwind also supports CME’s new AI compute futures initiative.
• Perpetual Futures Impact Assessment (June 4 & June 9 Conferences): Nasdaq was explicit that it does not believe the CFTC’s approval of Kalshi’s Bitcoin perpetual contract will impact its equities or options business. Tal Cohen stated: “Options have great utility — hedging, risk management, income generation, and expressing sentiment — whereas perps are more of a linear exposure product.” Nasdaq views perps as “more akin to levered ETFs, swaps, and CFDs than options.” Nasdaq also noted that U.S. regulators (CFTC and SEC) have not yet legally determined whether perpetuals are futures or swaps.
• CME Read-Through: Validates CME’s own position. The regulatory uncertainty around perpetuals (futures vs. swaps classification) is a key point CME management is likely to emphasize on the Q2 call. Nasdaq’s “complementary rather than competitive” framing is more measured than CME’s adversarial stance, which may be a point of differentiation in Q&A.
• Nasdaq-100 Methodology Changes (June 4 Conference): Nasdaq implemented meaningful changes to the Nasdaq-100 methodology effective May 1, including moving from annual to quarterly rebalancing, adjusting free float methodology, and introducing a “fast entry rule” for top 40 Nasdaq-listed companies (market cap ~$120B+).
• CME Read-Through: Quarterly rebalancing of the Nasdaq-100 increases the frequency of index-related hedging activity, which is a positive for CME’s equity index futures and options volumes. This is a structural tailwind for CME’s equity index ADV that may not be fully reflected in consensus.

Overall Peer Read-Through Summary: The peer commentary from ICE, CBOE, and NDAQ since Q1 earnings is broadly constructive for CME’s Q2 setup. The consistent themes are: (1) elevated open interest carrying forward into Q2 as a leading volume indicator; (2) a supportive macro backdrop (geopolitical risk, rate uncertainty, AI trade, retail engagement) driving derivatives demand; (3) industry-wide consensus that perpetual futures are complementary rather than directly competitive to institutional derivatives franchises; and (4) the Nasdaq-100 quarterly rebalancing as a structural tailwind for equity index volumes. The key risk flagged by all peers is the regulatory uncertainty around perpetual futures, which could be a headline risk for CME given its more adversarial public stance.

8. Insider Transaction Activity

Key Takeaway: The most notable transaction is CEO Terry Duffy’s open-market sale of 35,000 shares (~$10.4M at ~$298/share) on May 15 — approximately one month before the CEO transition announcement — which warrants attention given the timing. The bulk of other activity is routine director compensation grants (code “A”), not open-market purchases or sales.

Source: Insider Transaction Data (SEC Form 4 filings). The Duffy sale of 35,000 shares on May 15 is the most notable transaction. While the sale occurred approximately one month before the June 17 CEO transition announcement, it is not possible to determine from public filings alone whether this was related to the pending transition or was a routine liquidity event. The absence of a 10b5-1 plan flag in the data means this appears to be a discretionary sale. Director Shepard’s open-market purchase of ~339 shares on June 25 (near the stock’s recent lows around $225) is a small but directionally positive signal. No clustered open-market buys from senior management are present, which is notable given the stock’s ~17% decline since Q1 earnings.

— End of CME Group Q2 2026 Earnings Preview —